FiercePharma

Pfizer, on third try, wins FDA nod for biosimilar of blockbuster Epogen/Procrit

After a couple of misfires, Pfizer has finally won FDA approval for its biosimilar of anemia drug Epogen/Procrit, a drug whose U.S. sales generated about $1.8 billion last year for partners Amgen and ...
Healio

FDA approves Retacrit, an Epogen/Procrit biosimilar, for treatment of anemia

Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...
Drug Store News

Amgen recalls certain lots of Epogen, Procrit

THOUSAND OAKS, Calif. Several lots of two drugs used to treat anemia are being recalled due to possible contamination. Amgen said Friday that it was voluntarily recalling certain lots of Epogen and ...
FiercePharma

With patent clock ticking, Amgen plans to shutter Epogen plant

Other reasons for the stoppage aren't difficult to identify. Epogen and its sister drug Aranesp have never recovered from the safety issues that arose in 2010, when higher doses were linked to all ...
Medscape

Aranesp, Procrit, Epogen Linked to Risks of Pure Red Cell Aplasia, Anemia

Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via letter regarding revisions to the safety ...
Healio

Choice of erythropoiesis stimulating agent in ESRD

Please provide your email address to receive an email when new articles are posted on . There are currently four FDA (Food and Drug Administration) approved erythropoiesis stimulating agents (ESAs) ...
Medscape

First Epoetin Alfa Biosimilar Approved in the US

The US Food and Drug Administration (FDA) has approved the first biosimilar erythropoiesis-stimulating agent. The reference product is epoetin alfa (Epogen/Procrit, Amgen). The new biosimilar is ...
Renal & Urology News

Higher Conversion Ratio for Epoetin Beta to Darbepoetin Alfa

Fixed-Dose Phosphate Binder Schedules May Be Less than Ideal Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin. For Asian hemodialysis (HD) patients with ...
FierceBiotech

Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO) ...
ascopubs.org

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.

Value of caregiver ratings in evaluating the quality of life of patients with cancer. More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic ...
ascopubs.org

Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer ...

The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and ...